BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 760K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

19 articles for JJ Kulagowski

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Novel N1-(benzyl)cinnamamidine derived NR2B subtype-selective NMDA receptor antagonists.EBI
Merck Sharp & Dohme Research Laboratories
Novel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1.EBI
Argenta Discovery
Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.EBI
Genentech
Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2.EBI
Genentech
Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.EBI
Genentech
Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.EBI
Argenta Discovery
 
4-Heterocyclyl tetrahydropyridines as selective ligands for the human dopamine D4 receptorEBI
TBA
 
Tetramic acids as novel glycine site antagonistsEBI
TBA
1-Phenyl-8-azabicyclo[3.2.1]octane ethers: a novel series of neurokinin (NK1) antagonists.EBI
Merck Sharp & Dohme Research Laboratories
Synthesis and structure-activity relationships of 8-azabicyclo[3.2.1]octane benzylamine NK1 antagonists.EBI
Merck Sharp & Dohme Research Laboratories
Thiazoles and thiopyridines: novel series of high affinity h5HT(7) ligands.EBI
Merck Sharp & Dohme Research Laboratories
Orally efficacious NR2B-selective NMDA receptor antagonists.EBI
Merck Research Laboratories
Synthesis and sar of 2- and 3-substituted 7-azaindoles as potential dopamine D4 ligands.EBI
Merck Sharp & Dohme Research Laboratories
3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor.EBI
Merck Sharp and Dohme Research Laboratories
3'-(Arylmethyl)- and 3'-(aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-ones: orally active antagonists of the glycine site on the NMDA receptor.EBI
Merck Sharp and Dohme Research Laboratories
Aminoalkyl phenyl sulfones--a novel series of 5-HT7 receptor ligands.EBI
Merck Sharp and Dohme Research Laboratories
Substituted carboxamides as inhibitors of WDR5 protein-protein bindingBDB
Propellon Therapeutics
Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disordersBDB
Dana-Farber Cancer Institute
Phenyloxadiazole derivatives as PGDS inhibitorsBDB
Sanofi